The Clinton Health Access Initiative (CHAI) released the Hepatitis B Market Report, covering the latest trends in the hepatitis B diagnostic and treatment markets. This report is part of the market intelligence series that CHAI routinely publishes to highlight key updates on trends in the hepatitis C virus (HCV) and hepatitis B virus (HBV) markets.
The Hepatitis B Market Report expands upon CHAI’s preliminary HBV market insights first published in August 2021 and provides an overview of the supplier landscape for World Health Organization (WHO)-recommended HBV diagnostics and treatment drugs, outlining historical supply and pricing trends while highlighting global benchmark prices.
Key insights include:
HBV Treatment
- Approximately three million packs of tenofovir disoproxil fumarate (TDF) singles were exported by Indian generics to low- and middle-income countries in 2021, a 150 percent increase from the previous year
- TDF is accessed by HBV programs at one to 12 times the price accessed by HIV programs
- Strategies like pooled procurement and alternative financing mechanisms could be used by countries to access TDF therapy at price parity with HIV programs
HBV Diagnostics
- HBV rapid diagnostic tests (RDTs) prices remain consistent at around US$1 in most high-burden countries.
- HBV viral load pricing ranged from US$9.36-62
- Several HBV viral load suppliers offer global access pricing from US$9-16
- HBV viral load volumes from several major suppliers (non-exhaustive) demonstrate 315k – 484k sale volumes to select LMIC in recent years
- Multiple suppliers offer Hepatitis B e Antigen (HBeAg ) tests and combination rapid diagnostic tests
Financing continues to be a major barrier to the introduction and growth of HBV programs globally. In addition to countries mobilizing domestic resources to support programs, countries can explore donor investments (such as financing from Global Fund) to complement programming efforts. As countries introduce and scale triple elimination efforts for maternal and neonatal health across disease areas such as HIV, syphilis, and HBV, there is growing demand to improve service delivery through an integrated combination RDT.
Latest updated from Aligos Therapeutics and Arbutus Biopharma Corporation:
- Aligos Therapeutics initiates dosing with its small interfering RNA (siRNA) drug candidate, ALG-125755, in subjects with chronic hepatitis B (CHB)
- Arbutus completes enrollment in its Phase 2a clinical trial combining AB-729 with NA therapy and peginterferon alfa-2a in patients with chronic hepatitis B virus infection
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.